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SH3GL2Single nucleotide polymorphisms (SNPs) in the 3′-UTR region are emerging cis-regulatory factors associated
with the occurrences of several human diseases. SH3GL2, which is located at chromosome 9p21-22, is associated
with hyperplastic/mildly dysplastic lesions of the head and neck and has a long 3′-UTR with multiple SNPs. The
aim of the present study was to determine the susceptible allele(s) in the 3′-UTR SNPs of SH3GL2 in head and
neck squamous cell carcinoma (HNSCC). First, we screened the genotypes of all SNPs located in the 3′-UTR of
SH3GL2 in 110 controls and 147 cases in Indian populations by sequencing. A SNP (rs1049430:NG/T) that
showed only heterozygosity was further conﬁrmed by genotyping with an Illumina GoldenGate platform in
530 controls and 764 cases. Genotype-speciﬁc survival analysis of the HNSCC patientswas performed. In addition,
genotype-speciﬁc mRNA stability, isoform expression and protein expression were analyzed. SNP rs1049430
was not associated with disease occurrence, but it was associated with poor patient outcome. The G allele was
associated with decreased SH3GL2 mRNA stability, differential splicing and low protein expression. Thus, our
data demonstrate that the presence of the susceptibleG allele in SNP rs1049430 is associatedwith the inactivation
of SH3GL2 and could be used as a prognostic marker of HNSCC.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The Src-homology-3 domain (SH3) of intracellular proteins is an
evolutionarily conserved 50- to 60-amino acid module that is involved
in the transduction of signals for cell polarization, motility, enzymatic
activation and transcriptional regulation [26]. SH3-domain GRB2-like-2
protein (SH3GL2, also called endophilin-1) has been found to mediate
protein–protein interactions that are important for the endocytosis of
the epidermal growth factor receptor (EGFR) to allow for its homeostasis
[8]. Downregulation of SH3GL2 is associated with the development of
different human cancers, and upregulation of the gene is associated
with Alzheimer's disease [7,9,23,27,29]. In our previous study, frequent
alterations (deletion/promoter methylation) and reduced expression
of SH3GL2 have been found to be associated with hyperplastic/mild91 33 2475 7606.
.dysplastic lesions of the head and neck [10,17]. The prognostic impor-
tance of this gene has also been evaluated, and it has been suggested to
be a candidate tumor suppressor gene for the development of head
and neck squamous cell carcinoma (HNSCC).
SH3GL2 has 10 exons, with a short 5′-UTR and a long 3′-UTR
(approximately 1.4 kb in length) (http://asia.ensembl.org). The 3′-UTR
of SH3GL2 harbors multiple SNPs. It is evident that SNPs located in the
3′-UTR of a gene can regulate alternative polyadenylation and mRNA
stability [12,13,18], and their associations with different diseases,
including tumors, have been reported [1,5,6,15,21,22,24,30,31]. In
contrast with deletions and methylation events, allelic variations in
SNPs in the 3′-UTR of SH3GL2 have not yet been evaluated with regard
to their importance in themetabolism of this gene as well as their asso-
ciations with diseases, particularly HNSCC.
Therefore, the aim of this study was to determine the susceptible
allele(s) of 3′-UTR SNPs of SH3GL2 in Indian patients with HNSCC and
also to evaluate its importance in the progression and prognosis of
Table 1
Basic characteristics of case and control samples.
Variables Case (n = 764) Control (n = 530) p-Value
Gender, n (%)
Male 559 (73.2) 407 (76.7) 0.806 (NS)
Female 169 (22.1) 119 (22.4)
Unknown 36 (4.7) 4 (0.7)
Age, mean range 46.5 (20–88) 48.1 (22–85) NS
Tobacco
Yes 539 (70.5) 316 (59.6) 0.00004 (S)
No and unknown 225 (29.4) 214 (40.4)
NS: non-signiﬁcant and S: signiﬁcant.
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tiﬁed a candidate SNP rs1049430 (G N T) that showed heterozygosity in
the Indian population. Expression analysis (RNA/protein) of the different
alleles of this SNP suggested that the G′ allele could negatively regulate
the expression of this gene and that it was signiﬁcantly associated with
the clinical outcome of this disease.
2. Materials and methods
2.1. Patient population, tumor tissues, control population and cell lines
Tissue and blood samples from head and neck lesionswere collected
from patients at the Chittaranjan National Cancer Institute, Kolkata,
India. The samples were frozen immediately after collection at−80 °C
until use. Part of the freshly operated tissues was collected in TRIzol
(Invitrogen, USA) for RNA isolation. To perform a case–control study,
764 head and neck lesions from 764 patients receiving no prior treat-
ment and 530 blood samples from ethnically matched but unrelated
control individuals with no past or present history of HNSCC were
collected. Oral swabs and blood samples were collected from 20 control
individuals. This study was approved by the institutional ethical
committee, and written informed consent was obtained from the case
and control individuals. Among the 764 head and neck lesions, 253
were leukoplakia, and 511were invasive HNSCC. Detailed clinicopatho-
logical histories of the patients and information pertaining to the unre-
lated controls are presented in Table 1.
To observe genetic diversities among Indian populations, individuals
were recruited from three isolated populations, including the Rabha
(Tibeto-Burman, n = 32), Santhal (Austro-Asiatic, n = 19) and Madia
(Dravidian, n = 32) tribal populations. Written informed consent was
also obtained from the volunteers. Detailed clinicopathological historiesFig. 1. Summary of the samples used in different experiments. ‘n’ indicates the sample numbof the patients and information pertaining to the unrelated controls are
presented in Table 1.
The cell lines Hep2, KB and MCF7 were procured from the National
Center for Cell Sciences, Pune, India, and UPCI:SCC084 was kindly
provided by Prof. Susanne M. Gollin from the University of Pittsburgh,
PA. A summary of the total samples used in the different experiments
is shown in Fig. 1.
2.2. DNA extraction
Samples containing N60% dysplastic epithelial/tumor cells were ob-
tained for isolation of DNA according to the standard procedure [19].
High-molecular-weight DNA from tissue samples was extracted by
proteinase K digestion, followed by phenol/chloroform extraction.
Genomic DNA from peripheral blood lymphocytes was isolated using
QIAGEN Blood DNA Isolation Kits according to the manufacturer's
protocol.
2.3. RNA isolation and cDNA synthesis
Total RNAwas isolated from 10 primary HNSCC tumors and four cell
lines using TRIzol Reagent (Invitrogen, USA) according to the
manufacturer's protocol as described previously [17].
2.4. Genetic and epigenetic alteration analysis
In our previous study, the deletion and promoter methylation status
of SH3GL2has been published using the same set of 147HNSCC samples
[17].
2.5. Genotyping of SNP(s) located in the 3′-UTR of SH3GL2
The entire 3′-UTR region of SH3GL2 was ampliﬁed by PCR in 110
control samples, 147 tumor samples and 4 cell lines using two sets of
primers (Table S1). PCR products were analyzed by direct sequencing
in both the sense and antisense directions with a BigDye Terminator
Cycle Sequencing 3.1 Kit (Applied Biosystems, USA) according to the
manufacturer's instructions.
To perform a case–control study, the genotyping of informative
SNP(s) was conducted in 764 tumor and 530 control samples in a
batch of SNP genotyping experiments as described in our previous
study [20] using an Illumina GoldenGate genotyping platform, according
to the manufacturer's protocol.er. Del; deletion analysis, meth; methylation analysis, TN; tumor and adjacent normal.
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Fisher's exact test was used to evaluate case–control differences in
the distribution of rs1049430 genotypes and HNSCC risk. Four different
comparisons were made in the case–control study as follows: i) head
and neck lesions (leukoplakia + HNSCC) versus normal tissue; ii)
HNSCC versus leukoplakia; iii) HNSCC versus normal tissue; and iv)
leukoplakia versus normal tissue. For each set, p-values, odds ratios
(OR) and 95% CIs were determined. All statistical tests were 2-sided
and were considered signiﬁcant at a p b 0.05.
Complete follow-up data were obtained from the 147 HNSCC
patients. Curveswere calculated according to theKaplan–Meiermethod
for the 147 HNSCC samples, for which survivability was evaluated with
thismethodwith the log rank test for censored survival data. Alterations
(deletion/methylation) in SH3GL2 in the 147HNSCC samples have been
published in our previous paper [17]. A Cox-proportional hazardsmodel
was used to determine the statistical signiﬁcances of several potential
prognostic factors. From this model, we estimated the hazard ratio
(HR) for each potential prognostic factor with a 95% conﬁdence interval
(CI) in a multivariate fashion. All statistical analyses were performed
using statistical programs Epi Info 6.04b and SPSS 9.0 (SPSS, Chicago, IL).2.7. mRNA stability assay
Overnight subconﬂuent cultures of the cell lines Hep2 and MCF7
(1 × 106 cells) were treated with actinomycin-D (Sigma; 5 μg/ml) in
six 35-mm petri dishes [15,25]. A control without actinomycin-D was
cultured concomitantly in the same manner. After treatment, the cells
were harvested at different time points (0 h, 4 h, 8 h, 12 h, 24 h and
48 h) of incubation followed by total RNA isolation using TRIzol Reagent
(Invitrogen, USA) according to the manufacturer's protocol.Fig. 2. Allele distribution of SNP rs1049430 in HNSCC patients and different isolated control po
population, b) HNSCC disease population, c) isolated Santhal population, d) isolated Rabha pop
experiment. Percent (%) of each allele in each population is shown in the chart.Real-time quantiﬁcation of SH3GL2 mRNA was performed with an
ABI Prism 7500 using Power SYBR Green PCR Master Mix (Applied
Biosystems, USA), as described in our previous study [16]. The primers
used in this experiment are shown in Table S1.
2.8. Allele-speciﬁc expression assay
An allele-speciﬁc expression assay of the Hep2, KB and MCF7 cell
lines was performed according to the standard procedure [2,25]. Brieﬂy,
genomic DNA and corresponding cDNA of SH3GL2 were ampliﬁed
separately by PCR using primers encompassing all SNPs assessed. The
sequencing reaction was performed as described in an earlier section
(“Section 2.5”). For each sample, the peaks at the position of the SNP
for the genomic DNA versus the cDNA were determined. The primers
used in this experiment are shown in Table S1.
2.9. Isoform expression analysis
To determine the role of 3′-UTR genetic variations in SH3GL2 in its
differential alternative splicing, semi-quantitative reverse transcription
PCRwasperformed onHep2, KB andMCF7 cell lineswith speciﬁc primer
sets (Table S1). 18S rRNA was used as a housekeeping control. Brieﬂy,
PCR was performed for 35 cycles, and the products were electropho-
resed on 2% agarose gels and visualized with a Gel Documentation sys-
tem (BioRad, USA).
2.10. Immunohistochemical (IHC)/immunocytochemistry (ICC) analysis
Assessment of the protein expression of SH3GL2 was conducted by
immunohistochemical analysis for 20 primary HNSCC samples and by
immunocytochemical analysis for 20 normal exfoliated cells of oral
swab and cancer cell lines (MCF7, KB, and SCC084) according to thepulations. Pie-charts show the G and T allele frequencies of rs1049430 in a) Indian control
ulation and e) isolated Madia population. ‘n’ indicates the number of samples used in the
Table 2
Fig. 3. rs1049430 allele speciﬁc survival analysis of HNSCC patients. a) Kaplan–Meier estimation on overall survival in HNSCC patients of three genotype groups (GG, GT, TT) of SNP
rs1049430 irrespective of genetic alterations. b) The effect of rs1049430 on overall survival of the HNSCC patients having no genetic alterations of SH3GL2. c) The effect of rs1049430
on overall survival of the HNSCC patients with genetic alterations of SH3GL2. n; number of patients selected, alt+; genetic/epigenetic alteration present, alt−; genetic/epigenetic alteration
absent. Log rank p value indicates the signiﬁcance level. d) Allele speciﬁc mRNA stability analysis of SH3GL2: qRT-PCR analysis of SH3GL2 mRNA was performed after inhibition of
transcription by actinomycin-D treatment for different time points. Hep2 and MCF7 cell lines were taken for G and T allele containing mRNAs respectively. Sub-conﬂuent cultures of
the cell lines were treated with actinomycin-D (5 μg/ml). The cells were harvested after 0 h, 4 h, 8 h, 12 h, 24 h and 48 h of treatment and total RNA was isolated. SH3GL2 mRNA was
quantitated by SYBR green method and plotted against time.
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SH3GL2 (sc-10874), an HRP-conjugated rabbit anti-goat (sc-2020) sec-
ondary antibody, 3-3-diaminobenzidine (DAB), and a FITC-conjugated
secondary antibody (rabbit anti-goat, sc-2777) were purchased from
Santa Cruz Biotechnology Inc., USA. The slides were photographed with
a bright-ﬁeld microscope (Leica DM1000, Germany). Imaging of the
cover slips was performed with a ﬂuorescence microscope (Leica
DM4000B, Germany).
Staining intensity was determined independently by 2 observers
using a 4-tiered system as follows: low or negative (+), moderately
positive (++), strongly positive (+++) or intensely positive
(++++) [28]. The two scores were combined for the ﬁnal evaluation
of expression.Multivariate analysis of the SNP (rs1049430) with different clinicopathological
parameters.
Univariate Overall survival
Variable p value HR 95% CI for HR
rs1049430 b0.0001 1.9753 1.4872–2.6235
SH3GL2 ALT 0.0085 1.8849 1.1753–3.0231
Node 0.0205 1.7805 1.0930–2.9003
Stage 0.0706 0.7919 0.6150–1.0198
Histology 0.0114 0.6300 0.7470–1.2237
HPV 0.0398 0.6460 0.4258–0.9799
Tobacco 0.9075 1.0298 0.6274–1.6903
ALT, genetic alteration;HPV, humanpapillomavirus; bold letters indicate the signiﬁcant or
borderline signiﬁcant value.2.11. Bioinformatics analysis
Toﬁnd SNPs locatedwithin the 3′-UTR of the SH3GL2 gene, theNCBI
SNP database (http://www.ncbi.nlm.nih.gov/snp/) was used (Table S2).
Four publicly available algorithms, PicTar (http://pictar.mdc-berlin.de/),
TargetScan (http://www.targetscan.org/), Microcosm Targets (www.
ebi.ac.uk-srv/microcosm/) and DIANA microT (http://diana.pcbi.
upenn.edu/), were used to predict the human miRNAs (Table S3). The
secondary structure and free energy change (ΔG) of the SH3GL2
mRNA with the allelic variation of rs1049430 were predicted using
the mFOLD tool (http://mfold.rna.albany.edu/) [11].3. Results
3.1. Genotyping of the 3′-UTR SNPs of SH3GL2 in Indian populations
All of the SNPs except rs1049430were non-informative in the Indian
control population (Table S2). SNP rs1049430 showed 62% G and 38% T
alleles in the population (Fig. 2). However, differential allele frequencies
were observed in the three ethnic Indian tribal populations (Santhal,
Rabha and Madia), with signiﬁcant differences in allele frequencies in
Madia (p = 0.0018) and Rabha (p = 0.00036) compared with the
control population (Table S4). Among the cell lines, Hep2 contained
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(Table S4b). In the case–control study, comparisons of GT, GG and
GT+GGwith respect to the TT genotypewere performed. No signiﬁcant
association of the SNPwith the development of i) head and neck lesions
(leukoplakia + HNSCC) compared with normal tissue; ii) HNSCC
compared with leukoplakia; iii) HNSCC compared with normal tissue;
or iv) leukoplakia compared with normal tissue was observed
(Table S5).Fig. 4.Allele speciﬁc expression analysis of SH3GL2: Allele expression analysiswas performed b
region of SH3GL2. a) The genetic organization of SH3GL2with different primer locations used in
and 11 showing total two isoforms in GG containing cell line Hep2 and GT containing KB, one
primer set (2) and (3) from exons 9 and 11 respectively in Hep2, KB and MCF7 showing single
set (4) and (5) showed theband inHep2andKBbut noband inMCF7. b) The chromatogramsho
and T alleles of the SNPwere present in genomic DNA, but only G allelewas present inmRNA of
genomic DNA and no allele was expressed in mRNA.3.2. SNP rs1049430 and the prognosis of HNSCC
Survival analysis of HNSCC cases (n = 147) stratiﬁed by genotypes
revealed that the carriers of the GT and TT genotypes of SNP
rs1049430 of SH3GL2 had better survival rates compared with the GG
carriers (p = 0.0001) (Fig. 3a, b, c). A similar phenomenon was also
evident in the HNSCC patients without alterations in SH3GL2. However,
no signiﬁcant difference in disease prognosis was detected among they RT-PCR and sequencing of genomic DNA and correspondingmRNA at the SNP rs1049430
this study. PCR ampliﬁcation of SH3GL2mRNA using primer set (1) and (3) from exons 1
isoform in TT allele containing MCF7 cell line. PCR ampliﬁcation of SH3GL2 mRNA using
transcript. Ampliﬁcation of 3-UTR region of SH3GL2 in Hep2, KB and MCF7 using primer
wing the rs1049430 genotypeGG inHep2 cell line inboth genomicDNA andmRNA. BothG
KB cell line. Genotype of the SNP inMCF7 cell line showed that only T allelewas present in
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the tumors (p = 0.399). Genetic alterations in SH3GL2 have been
reported in the same set of samples (n = 147) in our previous study
[17]. Multivariate analysis showed that patients with the GG genotype
(p=0.0001;HR=1.97; CI=1.4872–2.6235) alongwith SH3GL2 alter-
ations (p= 0.0085; HR= 1.8849; CI= 1.1753–3.0231), a higher histo-
logical grade and nodal invasion (p = 0.0205; HR = 1.7805; CI =
1.0930–2.9003) in the absence of HPV infection (p = 0.0398; HR =
0.6460; CI = 0.6274–1.6903) in tumors had a worse prognosis
(Table 2).
3.3. The G allele is associatedwith less stable secondary structure of SH3GL2
mRNA
To predict the possible mechanism of SNP rs1049430 (G/T) in the
differential survival of HNSCC patients, we analyzed the RNA folding
and free energy change of SH3GL2 mRNA (Fig. S1). Bioinformatics
analysis revealed that the predicted minimal free energy (MFE) of the
secondary structure of mRNA for the T allele was lower than that for
the G allele (ΔG =−27.20 kcal/mol vs. ΔG =−25.16 kcal/mol). ThisFig. 5. Immunohistochemical/immunocytochemical analysis of SH3GL2 protein. a) Immunocyto
sion. Green arrows indicate the protein expression and localization. C4, C5 and C9 indicate the n
showing the cytosolic expression of SH3GL2. c) Immunohistochemical analysis of SH3GL2 in pr
expression in cell. (+) sign indicates the level of protein expression. 2333T, 3070T, 4534T and 2
promoter methylation present; D−M−,gene deletion and promoter methylation absent.result indicated that the mRNA structure associated with the T allele
may be more stable than that associated with the G allele.
The validation of bioinformatics analysiswas performed by an allele-
speciﬁc SH3GL2 mRNA stability assay of the Hep2 and MCF7 cell lines
(Fig. 3d). The expression of SH3GL2 was signiﬁcantly reduced in the
Hep2 cells after 12 h of actinomycin-D treatment. In contrast, in the
MCF7 cells, the expression of SH3GL2 did not change signiﬁcantly,
even after 48 h of actinomycin-D treatment. This ﬁnding indicates the
differential stability of SH3GL2 mRNA carrying the SNP with either the
G or T allele.
3.4. Allele-speciﬁc SH3GL2 expression analysis
To qualitatively assess the relative abundance of the allele-speciﬁc
mRNA level of SH3GL2, RT-PCR was performed using one primer set
encompassing the SNP (primer set 4 & 5) (Table S1) and another primer
set encompassing exons 8 and 10 (primer set 2 & 3) using cDNA from
the Hep2, KB and MCF7 cell lines.
Using the SNP primer set 4 & 5, no PCR product was found for the
MCF7 cells, whereas with the primer set 2 & 3, PCR products werechemical analysis of SH3GL2 in normal oral swab showingnuclear and cytoplasmic expres-
umber of normal swab samples.b) Immunocytochemical analysis in SCC084, KB andMCF7
imary HNSCC samples showing cytoplasmic expression. Black arrows indicate the protein
398T denote the registration number of HNSCC tumor samples. D+M+,gene deletion and
Table 3
Association of protein expression with genotype of SNP rs1049430 in control healthy
population and HNSCC patient population.
a)
Control samples Genotype of rs1049430 Protein level (ICC analysis)
C1 GT ++
C2 GG +
C3 GG +
C4 GG ++
C5 GT +
C6 TT +++
C7 GG +
C8 GT +
C9 TT +++
C10 GG +
C11 GG +
C12 GG +
C13 GT ++
C14 GG ++
C15 GG +
C16 GT ++
C17 GG +
C18 TT +++
C19 TT +++
C20 GG +
p = 0.01⁎
b)
HNSCC sample
reg. no.
Genetic
alterations
Genotype of
rs1049430
Protein level
(IHC analysis)
2398 D +M+ GG +
5219 D +M− GG +
1087 D−M+ GT +
2333 D−M− GG ++
5497 D−M− GT +++
1048 D−M− TT ++++
3070 D−M− GT ++
598 D−M− GG ++
5398 D−M− GG ++
914 D−M− TT +++
3941 D−M− GG ++
756 D−M− GT +++
5497 D−M− GT +++
5114 D−M− GG ++
2035 D−M− GG ++
4534 D−M− GG +
5540 D−M− GT +++
6329 D−M− TT +++
6907 D−M− TT ++++
6835 D−M− GT +++
p= 0.00032⁎
C(1–20), control healthy sample's reg. number; D+/−, deletion of SH3GL2 present/ab-
sent; M+/−; promoter methylation of SH3GL2 present/absent.
⁎ Signiﬁcant level.
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MCF7 cells in contrast with the Hep2 and KB cells (Fig. 4a). Sequencing
analysis of the PCR products resulting from the ampliﬁcation of the SNP
using the primer set 4 & 5 indicated that only the G allelewas evident in
both the Hep2 and KB cell lines, whereas genomic DNA sequencing of
the region showed that the G allele was evident in the Hep2 cells, the
G and T alleles were present in the KB cells, and the T allele was evident
in the MCF7 cells (Fig. 4b). Thus, it seems that the SH3GL2 mRNA with
the SNP containing the T allele had a shorter 3′-UTR region.
To determine whether the SNPs containing the G and T alleles have
any role on the transcript length variation of SH3GL2, expression analy-
sis was performed using the primer set 1 & 3 on the cell lines (Fig. 4a). A
larger transcript was common for all of the cell lines, whereas smaller
transcripts were observed in the Hep2 and KB cell lines, which were
probably due to alternative splicing.
3.5. Effect of SNP rs1049430 on SH3GL2 protein expression
Immunohistochemical/immunocytochemical analysis revealed the
differential expression of SH3GL2 depending upon the allelic variation
of the SNP in the normal oral swab, HNSCC samples and cell lines
(Fig. 5). In the normal oral swab, high cytoplasmic and nuclear expres-
sion of SH3GL2 was observed in cells with the TT genotype. It was
expressed at comparatively lower levels in the samples with either
the GT or GG genotype. In the cell lines, the expression of SH3GL2 was
greater in the MCF7 and KB cells with the TT and GT genotypes, respec-
tively, compared with the Hep2 cells with the GG genotype. Similar
results were observed in the HNSCC sampleswith no genetic/epigenetic
alterations in SH3GL2. The protein expression level of SH3GL2 was
signiﬁcantly correlated in the normal (p = 0.01) and HNSCC (p =
0.00032) patients with the rs1049430 genotypes (Table 3a & b).
4. Discussion
The aim of the present study was to identify the role of 3′-UTR
SNP(s) in the regulation of SH3GL2 expression and the susceptible
SH3GL2 allele(s) associated with HNSCC. To accomplish this aim, we
analyzed the genotypes of all SNPs in the 3′-UTR of SH3GL2. We found
that only one SNP, rs1049430, which is located in the 3′-UTR, was infor-
mative (i.e. heterozygous) in our populations. Our data provide
evidence that this new class of regulatory polymorphisms is an impor-
tant modiﬁer of HNSCC-related patient deaths.
To identify the regulatory mechanism of SNP rs1049430 involved in
the occurrence of HNSCC, a case–control study was performed of 764
cases and 530 controls using an Illumina GoldenGate assay platform.
The genotyping of the SNPwas also conducted in an isolated Indian con-
trol populationwith this method. No association of SNP rs1049430with
HNSCC was observed in the case–control study (Table S5). However,
when we compared the HNSCC allele frequencies of the patients in
the different populations with those of the isolated Indian control
population, signiﬁcant associations were observed for those in the
Rabha and Madia populations (Table S4). These ﬁndings indicate that
the Rabha and Madia populations might be differentially susceptible
to HNSCC compared with the control population. However, further
study is needed to explore thepopulation-speciﬁc disease susceptibility.
To determine whether there is any correlation of the genotype with
disease aggressiveness, allele-speciﬁc survival was determined for the
patients, and multivariate Cox regression analysis was performed. In
this study, we observed that the G allele of rs1049430-carrying patients
was more detrimental to survival compared with the T allele (Table 2).
Kaplan–Meier overall survival analysis revealed signiﬁcant (log rank
p = 0.001) survival advantages for the T allele carriers (Fig. 3). More-
over, survival analysis of the patients with no genetic alterations in
SH3GL2 showed signiﬁcant allele-speciﬁc survival advantages, but no
signiﬁcant survival differences were observed for the patients
possessing genetic alterations. These ﬁndings indicate that in additionto genetic alterations in SH3GL2, SNP rs1049430 plays a role in HNSCC
progression. In addition, these results indicate that either genetic alter-
ations in SH3GL2 and/or the G allele of rs1049430 are predictors of poor
patient survival. Similar to the ﬁndings of our study, 3′-UTR SNPs of
several genes, such asMDM4 and ITGB4, have been shown to be associ-
ated with the clinical outcomes of different tumors, such as non-small
cell lung cancer, ovarian cancer, and breast cancer [3,24,30]. To the
best of our knowledge, this is the ﬁrst report describing an association
of the 3′-UTR SNP genotype of SH3GL2 with the clinical outcome of
HNSCC.
In our previous study, we have observed that downregulation of
SH3GL2 due to genetic alteration is associated with overexpression of
EGFR and also with poor patient survival [17]. To determine the cause
of the SNP rs1049430-associated differential survival of the HNSCC
patient with no alterations in SH3GL2, the mRNA 3′-UTR secondary
structure and minimal free energy (MFE) change were calculated
using a bioinformatics tool. The predicted MFE of the secondary
Fig. 6. Proposed model for the regulation of SH3GL2 and clinical outcome of the patients: G allele containing mRNA isoforms of SH3GL2 are expressed with longer 3′-UTR as a result of
which greater number ofmiRNA get the accesses to the 3-UTR of SH3GL2. Consequently,miRNAmediated decay of SH3GL2 is enhanced. As the SH3GL2 expression is a predictor of patient
survivability, the patients with G allele containing SH3GL2 have poor clinical outcome. On the contrary, T allele of SH3GL2 isoforms is expressed with shorter 3-UTR resulting in lower
number of miRNA accession to 3′-UTR of SH3GL2. This occurrence leads to comparatively stable mRNA leading to better survivability of the patients.
1066 G.P. Maiti et al. / Biochimica et Biophysica Acta 1852 (2015) 1059–1067structure of the SH3GL2mRNAwith the T allele in rs1049430was lower
than that of the mRNA with the G allele (−27.20 vs.−25.16 kcal/mol)
(Fig. S1), indicating the increased stability of themRNAwith the T allele.
To support the mRNA stability prediction, an mRNA stability assay was
performed using cell lines with homozygous T and G rs1049430 alleles
after inhibition of transcription with actinomycin-D treatment (Fig. 3d).
We observed that the stability of the T allele-containing mRNA was
much higher than that of the G allele-containing mRNA, indicating
that a higher amount of SH3GL2 protein may be produced by the T
allele-containing mRNA due to its increased stability.
To further explore the possible regulatory mechanism of rs1049430
involved in SH3GL2 expression and in the clinical outcomes of HNSCC
patients, an allele expression assay was performed to assess different
cell lines with homozygous and heterozygous SNP alleles (Fig. 4). We
observed that the G allele containedwithin a UTR region encompassing
the SNPwas expressed in cell lines with homozygous (Hep2) or hetero-
zygous (KB) alleles. No T allele was observed in the heterozygous (GT)
or homozygous (TT) mRNA in KB or MCF7, respectively. This ﬁnding
might have been due to the differential termination of SH3GL2
pre-mRNA in the 3′-UTR region. It is possible that the G allele-
containing transcript could include the SNP, leading to a longer tran-
script. In contrast, the T allele-containing transcript did not include the
SNP, leading to a shorter transcript. An allele-speciﬁc differential 3′-
UTR length variation has also been reported in different genes, such as
IRF5, PPIL2, and PTER [12]. In addition, the two G allele-containing
transcripts and one T allele-containing transcript indicated the differen-
tial control of SH3GL2 splicing (Fig. 4a). A similar phenomenon has also
been reported in different geneswith SNPs in the 3′-UTR, such as L-RAP,
CAST, and GPR177 [14]. This ﬁndingmay have been due to the fact that
splicing machinery may be inﬂuenced by RNA allele-speciﬁc secondarystructure andmayplay an important role in exondeﬁnition for particular
transcripts [4].
Our data showed that the G allele-containing transcript, i.e. the
longer transcript, had a decreased stability compared with the T allele-
containing transcript, i.e. the shorter transcript. This ﬁnding might
have been due to the multiple miRNA binding sites in the longer
3′-UTR regions of SH3GL2, as revealed by bioinformatics analysis using
different on-line algorithms (Table S3, Fig. 6). The stability of allele-
speciﬁc SH3GL2 transcriptswas validated in protein expression analysis
(Fig. 5), which revealed lower protein expression in associationwith the
longer transcript compared with the shorter transcript.
Thus, the association of rs1049430 with SH3GL2 mRNA processing
and stability is important for determining the clinical outcome of
HNSCC and the poor prognosis of patients. However, a detailed, in
vitro, allele-speciﬁc expression proﬁle of the SNP is warranted to under-
stand its importance in the regulation of SH3GL2 expression.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.02.009.
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